一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
TIL（肿瘤浸润淋巴细胞）在非小细胞肺癌中的预后意义：一项系统综述与荟萃分析
英文原题：Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.
查看英文原题
Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这项全面的系统综述与荟萃分析证实了 TILs 在 NSCLC 患者中的预后意义。
中文摘要
背景
TIL（肿瘤浸润淋巴细胞）已被证明可作为多种癌症的预后生物标志物，但其对非小细胞肺癌（NSCLC）的预后意义仍不明确。
方法
我们全面检索 PubMed、EMBASE、Web of Science 和 Cochrane Library 数据库，查找截至 2023 年 12 月 19 日发表的相关研究。纳入标准为研究评估 NSCLC 患者 TIL 与总生存期（OS）及无病生存期（DFS）的关联。提取 OS 和 DFS 数据进行分析，通过计算合并风险比（HR）及相应 95% 置信区间（CI）评估 TIL 的预后意义。
结果
荟萃分析纳入 60 项研究，共涉及 15,829 例 NSCLC 患者。总体分析显示，存在 TIL 浸润的 NSCLC 患者 OS 显著改善（HR：0.67；95% CI：0.55–0.81）。按 TIL 亚型（CD8+、CD3+ 和 CD4+）进行的亚组分析均显示其对 OS 有利。FOXP3+ 则与较差 OS 相关，但结果未达统计学显著性（HR：1.35；95% CI：0.87–2.11）。
结论
这项全面的系统综述和荟萃分析证实了 TIL 对 NSCLC 患者预后的意义。TIL 浸润水平较高与较好预后相关，CD8+、CD3+ 和 CD4+ 亚型尤为如此。系统综述注册：PROSPERO，编号 CRD42023468089。
展开英文摘要原文
BACKGROUND
Tumor-infiltrating lymphocytes (TILs) have demonstrated potential as prognostic biomarkers across various cancer types. However, their prognostic implications in non-small cell lung cancer (NSCLC) remain ambiguous.
METHODS
An exhaustive electronic search was executed across the Pubmed, EMBASE, Web of Science, and Cochrane Library databases to locate relevant studies published up until December 19, 2023. Studies were eligible if they assessed the association between TILs and overall survival (OS) and disease-free survival (DFS) in NSCLC patients. The OS and DFS were subsequently extracted for analysis. The prognostic significance of TILs was evaluated by calculating the Pooled Hazard Ratios (HRs) and their corresponding 95% Confidence Intervals (CIs).
RESULTS
The meta-analysis incorporated 60 studies, which collectively included 15829 NSCLC patients. The collective analysis indicated that NSCLC patients exhibiting TILs infiltration demonstrated a significantly improved OS(HR: 0.67; 95%CI: 0.55-0.81). Subgroup analyses, based on TIL subtypes (CD8+, CD3+ and CD4+), consistently revealed a favorable prognostic impact on OS. However, it was observed that FOXP3+ was correlated with a poor OS (HR: 1.35; 95% CI: 0.87-2.11).
CONCLUSION
This comprehensive systematic review and meta-analysis substantiate the prognostic significance of TILs in patients diagnosed with NSCLC. Notably, elevated TILs infiltration correlates with a favorable prognosis, particularly among CD8+, CD3+ and CD4+ subtypes. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023468089 PROSPERO, identifier CRD42023468089.
论文信息
- 作者
- Yan Q、Li S、He L、Chen N
- 单位
- Department of Head and Neck Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.China
- 文献类型
- 系统综述 · 荟萃分析
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39372398 · DOI 10.3389/fimmu.2024.1476365
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →